Candel Therapeutics (CADL) vs Sana Biotechnology (SANA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Candel Therapeutics (CADL) has outperformed Sana Biotechnology (SANA) over the past year, gaining 51.8% versus a loss of 37.3%. Over five years, CADL leads with a +1.1% price change compared with -86.6% for SANA. Sana Biotechnology is the larger company by market cap ($835.2 million vs $760.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CADL | SANA |
|---|---|---|
| Share price | $9.94 | $2.79 |
| Market cap | $760.59M | $835.22M |
| 1-day change | +2.90% | 0.00% |
| YTD return | +75.93% | -31.45% |
| 1-year return | +51.76% | -37.30% |
| 5-year return | +1.12% | -86.58% |
| EPS (TTM) | $-1.50 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.00 | $6.55 |
| 52-week low | $4.35 | $2.61 |
| Distance from 52-week high | -29.00% | -57.40% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +118.81% | +202.15% |
| Average volume | 1.20M | 3.13M |
| Shares outstanding | 76.52M | 299.36M |
| Employees | 55 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CADL has outperformed SANA by 89.1 percentage points over the past year.
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
About Sana Biotechnology
SANA stock →Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
CADL vs SANA FAQ
Which is bigger, Candel Therapeutics or Sana Biotechnology?
Sana Biotechnology (SANA) is larger, with a market capitalization of $835.22M compared with $760.59M for Candel Therapeutics (CADL).
Which stock has performed better over the past year, CADL or SANA?
CADL returned +51.76% over the past 12 months, compared with -37.30% for SANA (price return, excluding dividends). Past performance does not predict future results.
Are Candel Therapeutics and Sana Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.